Join the Nonalcoholic Fatty Liver Disease group to help and get support from people like you.
Nonalcoholic Fatty Liver Disease News
Related terms: Nonalcoholic Steatohepatitis, Idiopathic Fatty Liver, Steatosis, Steatohepatitis, Fatty Liver, NASH, NAFLD, MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease
GLP-1 RA Use Linked to Reduced Cirrhosis Risk in MASLD, Diabetes
TUESDAY, Sept. 17, 2024 – For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with...
New Definition of Steatotic Liver Disease Improves Prediction of Kidney Disease
TUESDAY, Aug. 20, 2024 – Using a new classification of steatotic liver disease (SLD) based on the presence of metabolic dysfunction and alcohol consumption, metabolic dysfunction-associated...
Study Reveals MASLD, MetALD Responsible for One-Third of ICU Cirrhosis Cases
TUESDAY, Aug. 6, 2024 – Metabolic dysfunction-associated steatotic liver disease (MASLD)-related and metabolic and alcohol-related liver disease (MetALD)-related cirrhosis is responsible for...
Facial Temperatures Might Help Docs Diagnose Diabetes, Fatty Liver Disease
WEDNESDAY, July 3, 2024 – Screening for chronic illnesses like diabetes or fatty liver disease could one day be as simple as checking the temperature of your nose, eyes or cheeks. The temperature of...
Survodutide Tied to Significant Improvement in Fatty Liver Disease
MONDAY, June 17, 2024 – Most patients taking survodutide, a dual agonist of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor, experience significant improvement in metabolic...
Tirzepatide Beneficial for Resolution of MASH in Patients With MASH, Fibrosis
THURSDAY, June 13, 2024 – For patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-severe fibrosis, 52 weeks of tirzepatide is more effective than placebo for...
Experimental GLP-1 Med Might Be Breakthrough Against Fatty Liver Disease
MONDAY, June 10, 2024 – An experimental 'supercharged' form of popular GLP-1 weight-loss meds could help ease fatty liver disease, a new trial suggests. The drug under development, survodutide,...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...
MRE-Liver Stiffness Measure Better for Varices in NAFLD Cirrhosis
WEDNESDAY, May 8, 2024 – For patients with obesity and nonalcoholic fatty liver disease (NAFLD) compensated cirrhosis (CC), liver stiffness measurement (LSM) by magnetic resonance elastography (MRE)...